NOTCH1 and cancer: Thus, the MAb characterized in this study not only can effectively block “Gain- of function” mutant Notch1 signaling due to its higher affinity, but also affect the cancer cells with higher expression of Notch1 with inhibition of Notch signaling in addition to making them more sensitive to the drugs by increasing retention of the drugs.